title: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.
abstract: OBJECTIVE
  To determine if the hormonal imbalance in women with polycystic ovary syndrome (PCOS) continues into and after menopause and to analyze factors constituting an increased risk for developing metabolic disorders.
  
  
  METHODS
  The study was a transectional retrospective cohort follow-up of patients with PCOS.
  
  
  METHODS
  The women with PCOS were recruited from hospital clinics, and referents were randomized from a population study of women.
  
  
  METHODS
  Thirty-three women ages 40 to 59 years with ovarian histopathology typical of PCOS at wedge resection 22 to 31 years previously; 132 age-matched referents were analyzed.
  
  
  METHODS
  Clinical data were collected via a questionnaire supplemented with an interview in connection to a clinical examination that also included fasting venous sampling.
  
  
  RESULTS
  Infertility, hirsutism, and oligomenorrhea were more common among the subjects with PCOS, but there was a considerable spontaneous restitution of cyclic regularity with time. Women with PCOS were more often hysterectomized and entered menopause later compared with referents. The hormone data show a typical profile for PCOS. Compared with referents women with PCOS showed marked increase in prevalence of central obesity, higher basal serum insulin concentrations, and a higher prevalence of diabetes mellitus and hypertension.
  
  
  CONCLUSIONS
  Perimenopausal women with PCOS have an increased morbidity in hypertension and diabetes mellitus that adds to the classic symptoms, such as anovulation, hirsutism, and infertility.
authors.affiliation: Department of Obstetrics and Gynecology, Sahlgrenska Hospital, Göteborg, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Dahlgren
authors.forename: S
authors.initials: S
authors.lastname: Johansson
authors.forename: G
authors.initials: G
authors.lastname: Lindstedt
authors.forename: F
authors.initials: F
authors.lastname: Knutsson
authors.forename: A
authors.initials: A
authors.lastname: Odén
authors.forename: P O
authors.initials: PO
authors.lastname: Janson
authors.forename: L A
authors.initials: LA
authors.lastname: Mattson
authors.forename: N
authors.initials: N
authors.lastname: Crona
authors.forename: P A
authors.initials: PA
authors.lastname: Lundberg
mesh_terms: D000328:Adult; D000728:Androgens / Q000097:blood; D015992:Body Mass Index; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004970:Estrone / Q000097:blood; D005260:Female; D005298:Fertility; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007328:Insulin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation; D008875:Middle Aged; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000503:physiopathology* / Q000601:surgery*; D011388:Prolactin / Q000097:blood; D013972:Thyrotropin / Q000097:blood
chemical_list: D000728:Androgens; D007328:Insulin; D004970:Estrone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin